A new Northwestern Medicine study has uncovered previously unidentified intracellular mechanisms in the peripheral nervous system that cause Charcot–Marie–Tooth Type 2B disease, findings that may inform the development of new targeted therapies.
A pair of recent studies from the laboratory of Evangelos Kiskinis, PhD, have uncovered novel cellular mechanisms that are involved in two types of genetic ALS, providing support for future development of targeted therapies to treat the disease.
Northwestern investigators, clinicians, and people living with ALS convened in the Feinberg Pavilion for the 13th annual Les Turner Symposium on ALS to celebrate and share new scientific breakthroughs that improve the understanding of ALS and advancements in treating the disease.
In a recent article published in Molecular Cell, the laboratory of Ali Shilatifard, PhD, provided a comprehensive overview of the current understanding of the elongation stage of DNA transcription and how its dysregulation is associated with developmental defects, disease and aging.
Northwestern Medicine investigators have identified a novel therapeutic agent that is effective in treating metastatic cancer and brain metastases, according to a recent study published in the Journal of Clinical Investigation.
Deborah Clements, MD, the chair and the Nancy and Warren Furey Professor of Family and Community Medicine, has been honored with the American Academy of Family Physicians’ Thomas W. Johnson Award for her significant contributions to family medicine education.
Social media posts with visual abstracts — images with text and icons that convey a study’s methods and findings — of clinical trials published online in peer-reviewed academic journals increased social media engagement compared to social media posts with article figures, according to a recent research letter published in JAMA.
A novel cellular pathway regulates DNA damage and structural changes in cardiomyocytes which contributes to the development of cardiac hypertrophy according to a Northwestern Medicine study published in Circulation.
Combining an immune checkpoint inhibitor with standard chemotherapy improved quality of life for patients with advanced stomach cancer or esophageal cancer compared to chemotherapy alone, according to recent findings published in The Journal of Clinical Oncology.
Now in its second year, Feinberg’s Research Intensive Scholarly Emphasis (RISE) program supports medical students engaging in an additional year of research during their medical school career.